Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC Formalizes Patient Advisory Council to Provide Insights and Guidance on Patient Perspectives for Pipeline Therapies
Patient Advisory Council to include advocates from the inherited retinal diseases global community  New Patient Advisory Council to focus initially on Company ’ s clinical stage programs for X-linked retinitis pigmentosa (XLRP) GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Aug.
View HTML
Toggle Summary AGTC to Present at the Wedbush PacGrow Virtual Healthcare Conference on August 11, 2020
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial
FDA feedback allows for forward program development Company reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities enable rapid clinical development GAINESVILLE, Fla. and CAMBRIDGE, Mass. , July 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic
View HTML
Toggle Summary AGTC Set to Join Russell 3000® and 2000® Indexes
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , June 24, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC Announces Significant Productivity and Quality Enhancement To Its Proprietary Manufacturing Process
Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , June 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of
View HTML
Toggle Summary AGTC to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on June 23, 2020
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , June 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC Launches Nationwide Mobile Vision Testing Program for Patients Enrolled in Its Ongoing Phase 1/2 Clinical Trials
Mobile vision testing unit enables X-linked retinitis pigmentosa and achromatopsia clinical trial patients to maintain important scheduled study assessments during COVID-19 pandemic GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , June 15, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation
View HTML
Toggle Summary AGTC Announces Publication of Positive Preclinical Data that Provides Foundational Scientific Evidence for its Ongoing Clinical Program in Patients with X-Linked Retinitis Pigmentosa (XLRP)
 -   Administration of AGTC’s proprietary adeno-associated virus (AAV) vectors expressing variants of the RPGR gene corrected early markers of disease and provided evidence of a rescue effect in an animal model of XLRP, with a favorable safety profile - GAINESVILLE, Fla. , and CAMBRIDGE, Mass.
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2020
- Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2H 2020 - - Company on track for End of Phase 2 meeting in Q2 2020 - - Company sees minimal COVID-19 impact to date - - Company to host conference call and webcast today at 8:00am ET - GAINESVILLE, Fla.
View HTML
Toggle Summary AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 13, 2020
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , May 06, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Visionary science for life changing cures.